US FDA Gives Medtech 15-Month Deadline To Comply With Postmarket Order
This article was originally published in SRA
Executive Summary
Medical device manufacturers operating in the US have 15 months after receiving a postmarket surveillance study order from the Food and Drug Administration to begin the mandated studies, the agency says in a May 16 final guidance1.